A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).

Mehmet  Akce

Consulting or Advisory Role - AstraZeneca; Curio Science; Eisai; Exelixis; GlaxoSmithKline; Ipsen; Isofol Medical; QED Therapeutics

Research Funding - Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); IMPAC Medical Systems (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); RedHill Biopharma (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); Xencor (Inst)

Siwen  Hu-Lieskovan

Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genmab; Guidepoint Global; Regeneron; Xencor

Matthew  Reilley

Stock and Other Ownership Interests  - Molecular Templates

Honoraria - BMS; Natera

James Fredric  Strauss

Leadership - Dialectic Therapeutics

Stock and Other Ownership Interests  - Abbott Laboratories; Abbvie; Bristol-Myers Squibb; Intuitive Surgical; Johnson & Johnson; Merck; Regeneron

Consulting or Advisory Role - Binhui Biopharmaceuticals, Ltd. (Inst); Synlogic (Inst)

Jennifer M.  Specht

Honoraria - Daiichi Sankyo; GE Healthcare; GlaxoSmithKline

Consulting or Advisory Role - Daiichi Sankyo; GE Healthcare; GlaxoSmithKline

Research Funding - Abbvie (Inst); Cascadian Therapeutics (Inst); Celcuity (Inst); Genentech (Inst); Merck (Inst); Minerva Biotechnologies (Inst); Myriad Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Seagen (Inst); Xencor (Inst)

Travel, Accommodations, Expenses - GE Healthcare; GlaxoSmithKline; Nektar

Mark N.  Stein

Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Exelixis; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Vaccitech; Xencor

Research Funding - Advaxis (Inst); Bellicum Pharmaceuticals; Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)

Judy S.  Wang

Consulting or Advisory Role - BioNTech; Janssen Research & Development; Stemline Therapeutics

Speakers' Bureau - AstraZeneca; Eisai

Research Funding - Aevi Genomic Medicine (Inst); Agenus (Inst); Artios (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bayer Health (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Biosplice (Inst); BioTheryX (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); CicloMed (Inst); Clovis Oncology (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Forty Seven (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immune-Onc Therapeutics (Inst); Immunogen (Inst); Jacobio (Inst); Janssen Research & Development (Inst); Klus Pharma (Inst); Kymab (Inst); Loxo (Inst); LSK BioPharma (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Nurix (Inst); Olema Oncology (Inst); ORIC Pharmaceuticals (Inst); Phoenix Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PureTech (Inst); QiLu Pharmaceutical (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Stemline Therapeutics (Inst); StingThera (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); TeneoBio (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Treadwell Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)

Jennifer Hsing  Choe

Consulting or Advisory Role - Blueprint Medicines; Exelixis; Sanofi/Regeneron

Research Funding - Adlai Nortye; AstraZeneca/Merck; Compass Therapeutics; Exelixis; Genmab; Merck; Regeneron; Xencor

Rom  Leidner

Research Funding - Bristol-Myers Squibb (Inst)

Other Relationship - Celldex (Inst); Clinigen Group (Inst); OncoSec (Inst)

Diwakar  Davar

Honoraria - Array BioPharma; Immunocore; Instil Bio; Merck; Tesaro; Vedanta Biosciences

Consulting or Advisory Role - Instil Bio; Shionogi (I); Vedanta Biosciences

Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)

Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy

Gerald Steven  Falchook

Employment - HealthONE; Sarah Cannon Research Institute

Honoraria - Rocky Mountain Oncology Society

Consulting or Advisory Role - EMD Serono; Fujifilm (Inst); Inspirna (Inst); Navire (Inst); Predicine (Inst); Regeneron (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Turning Point Therapeutics (Inst)

Speakers' Bureau - Total Health Conferencing

Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); Accutar Biotech (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Navire (Inst); NiKang Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); Poseida (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Silicon Therapeutics (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst)

Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy

Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute

Shubham  Pant

Honoraria - 4D Pharma

Consulting or Advisory Role - Ipsen; Xencor; Zymeworks

Research Funding - 4D Pharma (Inst); Arcus Biosciences (Inst); ArQule (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Onco Response (Inst); Purple Biotech (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)

Ezra E.W.  Cohen

Stock and Other Ownership Interests  - Kinnate Biopharma

Consulting or Advisory Role - Bayer; BioNTech; Debiopharm Group; Eisai; Gilead Sciences; Merck; MSD; Regeneron

Breelyn A.  Wilky

Consulting or Advisory Role - Adaptimmune; Adcendo; Daiichi Sankyo; Deciphera; Epizyme; Polaris; SpringWorks Therapeutics

Research Funding - Agenus; Exelixis

Travel, Accommodations, Expenses - Adaptimmune; Daiichi Sankyo; Deciphera

Benjamin  Thompson

No Relationships to Disclose

Raphael  Clynes

Employment - Xencor

Leadership - Xencor

Stock and Other Ownership Interests  - Xencor

Travel, Accommodations, Expenses - Xencor

Lingling  Li

Employment - Xencor

Stock and Other Ownership Interests  - Xencor

Travel, Accommodations, Expenses - Xencor

Patricia  McGovern

Employment - Xencor

Stock and Other Ownership Interests  - Xencor

David Neal  Liebowitz

Employment - DNAtrix; Xencor

Leadership - DNAtrix

Stock and Other Ownership Interests  - DNAtrix; Xencor

Consulting or Advisory Role - Vaxart

Patents, Royalties, Other Intellectual Property - Genentech; Xencor